2024 ADPD Poster
2024 ADPD Poster:
Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug (ACU193)-Amyloid Βeta Oligomer Complexes in Human CSF.
2024 AAN Presentation
2024 AAN Presentation:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
2024 AAN Poster
2024 AAN Poster:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
2023 AAIC Presentation
2023 AAIC Presentation:
Topline results of INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.
2023 CTAD Presentation
2023 CTAD Presentation:
INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers.
2023 CTAD Poster
2023 CTAD Poster:
INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease.
2023 CTAD Poster
2023 CTAD Poster:
Incorporating the Study Participant’s Voice into Early Development of ACU193 for Early Alzheimer’s Disease: A Qualitative Interview Study Following Participation in the INTERCEPT-AD Study.
2023 CTAD Poster
2023 CTAD Poster:
ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay of Target Engagement for the sAβO-Selective Antibody ACU193 in INTERCEPT-AD.
2021 CTAD Presentation
2021 CTAD Presentation:
Phase 1 trial design for ACU193, a monoclonal antibody that selectively binds soluble Aβ oligomers.
